AUDEARA

ASX Announcement
30 July 2026

Q4 FY26 Quarterly Activities Report & Appendix 4C

Audeara Ltd (ASX: AUA) ('Audeara' or 'the Company') is pleased to provide the following update for the three-month period ended 30 June 2026 ('Q4 FY26').

Highlights

Financial[1]

- Receipts from customers of $709k contributed to full-year cash receipts of $4.2m
- Quarterly unaudited Group revenue[1] of $0.47m contributed to full-year unaudited revenue of $4.44m, compared with $3.786m in FY25
- Net operating cash outflows of $795k for the quarter and $415k for FY26
- FY26 net operating outflows market the lowest in Company history and reiterate Audeara's focus on achieving consistent profitability
- Australian wholesale revenue of $376k for Q4 and $2.6m for FY26, up 46.4% when compared with ~$1.79m in FY25
- Cash and cash equivalents of $0.74m at 30 June 2026

Operational developments

- First customer program under the Optek chip-level AI audio licensing agreement advancing - now close to commercial production
- Exclusive Australian market deployment agreement secured with Shokz Health Global for the customised OpenLearn Small assistive listening solution
- Commencement of a large-scale Auracast™ rollout across Bolton Clarke's 43 retirement villages, beginning at Carrington Retirement Village in Queensland
- Continued progression of Clinico white-label Auracast™ programs and broader connected-listening opportunities across healthcare, education, community and event environments
- Expanded international engagement through ACAud 2026, SusHi Tech Tokyo 2026 and the Asia Summit on Global Health 2026

Outlook

- Focus on converting AUA Technology programs into repeatable licensing and partner-led revenue while maintaining Australian wholesale momentum and disciplined cash management

[1] All references to revenue in FY26 are unaudited revenues.

Management commentary

Audeara CEO and founder, Dr James Fielding said:

> "The June quarter was another demonstrated period in a year in which Audeara strengthened its commercial base and expanded the number of pathways through which our technology can reach customers. Australian wholesale continued to underpin operations, while AUA Technology programs advanced across AI licensing, Auracast™, education and partner-led product development.
>
> "During the quarter, the first customer program under our Optek licensing relationship moved close to commercial production, with development completed and final production-readiness activities underway. This is an important step in demonstrating that Audeara's AI audio capabilities can progress from development toward deployment directly on semiconductor platforms, creating a scalable licensing pathway without requiring Audeara to manufacture the finished product or own the end-customer channel.
>
> "At the same time, we secured exclusive Australian market deployment rights for a customised ShokzHear product focused on children's listening and learning, and commenced the Bolton Clarke rollout across 43 retirement villages. These programs demonstrate the breadth of the platform: supporting listening in classrooms, clinics, retirement communities, consumer audio and global OEM and ODM products.
>
> "Entering FY27, our focus remains on commercial conversion. We are working to turn the programs we have built on strong foundations and validated during FY26 into repeatable product, service and licensing revenue, while maintaining disciplined cash management and continuing to strengthen the Australian wholesale channel."

Financial Overview

Operating cash flow for the quarter will reflect the timing of customer receipts, inventory and manufacturing payments, engineering investment and active management of supplier payments.

- Cash receipts of $709k
- Annual cash receipts of $4.2m, a record high and up 11.1% from FY25
- Quarterly unaudited revenues of $470k, taking total FY26 revenue to $4.44m
- Payments to related parties, including directors' fees, of $114k
- Net operating cash outflows of $795k for the quarter, largely driven by strategic inventory build
- Total net operating cash outflows of $415k on FY26, highlighting ongoing focus on cash preservation
- Cash at bank as at 30 June 2026 of $0.74m
- Research and development: $112k
- Product manufacturing and operating costs: $528k
- Staff costs: $522k
- Administration and corporate costs: $288k

Annual Cash Receipts vs. Net Operating Cash Flow



Annual Revenue (FY26 unaudited)



Operational Overview

Australian Wholesale and Clinical Channel

Audeara's Australian wholesale channel continued to provide the Company's core near-term commercial base during the June quarter. Q4 wholesale revenue of $376k contributed to full-year wholesale revenue of $2.62m, compared with ~$1.79m in FY25 and highlighting a 46.4% increase on the previous corresponding period.

The performance continues to be supported by repeat orders from established wholesale customers, the release of the Company's Auracast™ portfolio into national accounts, and continued engagement with hearing clinics and audiology professionals.

Exclusive Australian Agreement with Shokz Health Global

During the period, Audeara secured exclusive Australian market deployment rights from Shokz Health Global Limited (ShokzHear), the healthcare-focused division of Shokz, for a customised assistive listening solution to be marketed as OpenLearn Small by ShokzHear.

The customised product is being developed for the Australian education market using Audeara's feedback on functionality, size and audio tuning parameters. ShokzHear will undertake product customisation and manufacturing based on the agreed requirements.

The program targets a large and underserved listening-and-learning need. Across Australia, up to an estimated 600,000 school-aged children experience functional listening challenges, often associated with fluctuating hearing loss. These challenges can affect speech access, classroom participation, confidence and longer-term learning outcomes, particularly in regional and remote communities.

OpenLearn is focused on educational settings where background noise and distance from the teacher can make speech difficult to access. The Company expects to place first orders for the product later in calendar 2026 following initial customer orders.

The agreement provides a pathway into fully funded state and national government programs and charitable channels, supporting scalable deployment through institutional procurement while maintaining a capital-efficient model and low customer-acquisition costs.

The agreement has an initial two-year term and supports Audeara's broader strategy of expanding its hearing-health platform in partnership with globally recognised hardware providers.

Bolton Clarke Auracast™ Rollout

Audeara commenced what is believed to be a world-first rollout of Auracast™ technology across Bolton Clarke's retirement living network, beginning at Carrington Retirement Village in Parkinson, Queensland in May 2026.

The rollout is expected to extend across Bolton Clarke's 43 retirement villages nationally and represents one of the first known large-scale implementations of Auracast™ technology within a retirement living environment globally.

Delivered in partnership with Bolton Clarke, the rollout will see Auracast™ enabled listening solutions installed across village community centres to support clearer and more accessible shared-listening experiences during communal activities and events.

The deployment provides Audeara with a reference implementation for Auracast™ enabled shared-listening environments at scale and supports the Company's connected-listening strategy across aged care, healthcare, accessibility and community environments.

Research conducted by Bolton Clarke Research Institute indicates ~45% of village residents are affected by hearing loss, impacting their ability to remain connected with their community, providing another major market opportunity for Audeara.

Auracast™ Platform Expansion – Clinico Inc. and Partner-led Programs

During the quarter, Audeara continued to progress the Auracast™ platform expansion with Clinico Inc. announced in March 2026. The initiative includes multiple white-label commercial programs, integration of Audeara's BT-03 Audio Broadcaster and personalised listening technology, and partner-led deployment across healthcare, education, university and entertainment environments.

Initial purchase orders secured during the prior quarter supported commencement of the commercialisation process. During Q4, activities continued across product development, certification, manufacturing planning and go-to-market preparation for the relevant programs.

The Clinico programs build on the successful launch of the Clinico Sound Earbuds CS1 in Taiwan and provide an additional pathway for the AUA Technology division to scale through partner-owned brands and channels.

More broadly, Auracast™ device sales and commercial engagement continued across Australia, Japan and the United States, with further market discussions underway in Europe and Asia.

AUA Technology – AI Audio Licensing with Optek Microelectronics

Audeara continued development under its chip-level AI audio licensing agreement with Optek Microelectronics during the quarter. Audeara's AUAI algorithms, including AI Noise Reduction and Media Personalisation, are being integrated directly into Optek system-on-chip platforms for deployment across global OEM and ODM customer programs.

The first customer program has completed its core development phase and is close to commercial production, with final production-readiness, manufacturing and customer processes underway. The Company has not yet recognised the program as having commenced commercial production.

Development of a second product program has also been completed and the program is progressing through final customer validation ahead of potential commercial production.

Once customer programs enter commercial production, the licensing model is expected to generate fee-per-chip revenue and provide a scalable pathway for Audeara's proprietary AI audio technology to be deployed across multiple products and brands without requiring the Company to manufacture the finished hardware.

China Market Update

Following NMPA certification and initial market testing with the Company's partner in China, work continued during the quarter to refine and optimise the go-to-market strategy for the personalised hearing product across China's primary e-commerce and online healthcare platforms.

The partner's strategic review and market testing have provided insights into product-market fit, channel positioning and the requirements for scaled commercialisation. These insights continue to be incorporated into the commercial strategy.

The Company remains focused on the long-term opportunity available through the capital-light licensing model, while recognising that the timing and scale of commercial sales will depend on successful execution of the refined partner-led strategy.

Industry and International Engagement

The June quarter included a significant program of industry and international engagement supporting Audeara's broader connected-listening and hearing-accessibility strategy.

ACAud 2026 National Congress

Audeara showcased its expanding portfolio of personalised listening, assistive audio and Auracast™ enabled solutions at ACAud 2026 National Congress, held from 22–24 April 2026.

Audiology remains an important wholesale and clinical engagement channel for Audeara. ACAud provided an opportunity to strengthen relationships with existing partners, engage with new clinics and industry stakeholders, and support awareness of emerging shared-listening technologies and connected-listening applications.

The event also enabled the Company to demonstrate how listening technologies are extending beyond traditional personal listening environments into shared healthcare, education, hospitality and community settings.

SusHi Tech Tokyo 2026

Audeara represented Queensland innovation at SusHi Tech Tokyo 2026 from 27–29 April 2026 as part of the Queensland Government and Trade and Investment Queensland delegation.

SusHi Tech Tokyo brought together government, infrastructure, healthcare, investment and emerging-technology stakeholders to explore solutions relating to ageing populations, accessibility, smart cities and future urban infrastructure.

Participation provided Audeara with opportunities to engage with international stakeholders across healthcare, accessibility, infrastructure and technology sectors, while showcasing the Company's listening-technology platform and connected-listening initiatives.

Asia Summit on Global Health 2026

Audeara showcased its hearing-accessibility and connected-listening solutions at the Asia Summit on Global Health 2026 on 11–12 May 2026 as part of the Australian national delegation, supported by Trade and Investment Queensland and Austrade.

The summit brought together healthcare leaders, government representatives, investors, hospital groups and healthcare-technology companies from across the Asia-Pacific region. Participation positioned Audeara within broader international discussions relating to healthcare accessibility, ageing populations and emerging listening technologies.

Japan Market Development

The Company continued to support its Japanese distributor following receipt of follow-on orders during the March quarter. Engagement through SusHi Tech and associated partner meetings supported further market development across assistive listening, healthcare and connected-listening applications in Japan.

The Company also signed on a new distributor Pola Digital with an extensive subdistributor network with extensive history in government IT, education, infrastructure and entertainment venues.

Collectively, the Company's international activities reflect increasing interest in technologies that support more accessible, flexible and connected listening experiences across healthcare, community and public environments.

Corporate and Technology Leadership Transition

During the quarter, Audeara announced the transition of co-founder and Chief Technology Officer Alex Afflick from his full-time executive role. A structured handover process was implemented to transfer responsibilities and technical knowledge across the Company's engineering and leadership teams.

The Board and management acknowledge Mr Afflick's contribution to the development of Audeara's core technology platform. The transition has been managed to maintain continuity across existing product-development, software, firmware and licensing programs.

Outlook

Audeara enters FY27 with a broader portfolio of commercial pathways across Australian wholesale, education, retirement living, Auracast™ enabled shared listening, partner-led product programs and chip-level AI audio licensing.

Near-term priorities include:

- Progressing the first Optek customer program through final production-readiness activities and supporting the second program through customer validation
- Converting the ShokzHear OpenLearn Small agreement into initial customer orders and commercial deployment
- Supporting the Bolton Clarke rollout and using the deployment as a reference model for additional healthcare, aged-care and community opportunities
- Progressing Clinico white-label programs through certification, production and commercial launch activities
- Maintaining Australian wholesale and clinical-channel momentum
- Managing working capital, supplier payments and operating expenditure in line with the timing of customer receipts and commercial programs

The timing of revenue and cash receipts will continue to reflect customer validation cycles, production schedules, order timing and partner-led commercialisation processes. The Company remains focused on converting its technology portfolio into recurring and scalable revenue while maintaining disciplined capital management.

This announcement has been authorised by the Board of Audeara Limited.

For more information please visit, audeara.com.

CORPORATE & MEDIA ENQUIRIES

Dr James Fielding
Managing Director and Chief Executive Officer

james.fielding@audeara.com

INVESTOR ENQUIRIES

Henry Jordan
Six Degrees Investor Relations

henry.jordan@sdir.com.au

ABOUT AUDEARA

Feel connected, your way.

Audeara Limited (ASX: AUA) is a global hearing health leader specialised in innovative listening solutions for people with hearing challenges.

We are passionate about redefining hearing health, with a particular focus on delivering products that provide world-class tailored listening experiences.

We care about connecting people with experiences that bring them joy - whether that's watching a favourite TV show, FaceTiming family or listening to music with confidence.

All Audeara products are purposefully designed and engineered in Australia with precision detail and state-of-the-art technology. Each product delivers optimum listening experiences to enhance quality of life for people of all ages and abilities.

Audeara sells its products through distributors and resellers in Australia, Europe, Asia and North America, and through e-commerce channels.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

AUDEARA LIMITED

ABN	**Quarter ended ("current quarter")**
27 604 368 443	30 June 2026

	Consolidated statement of cash flows	**Current quarter $A'000**	**Year to date (12 months) $A'000**
1	**Cash flows from operating activities**		
1.1	Receipts from customers	709	4,212
1.2	Payments for		-
(a)	research and development	(112)	(495)
(b)	product manufacturing and operating costs	(528)	(2,044)
(c)	advertising and marketing	(54)	(220)
(d)	leased assets	(1)	(3)
(e)	staff costs	(522)	(2,214)
(f)	administration and corporate costs	(288)	(927)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	1	11
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	1,265
1.8	Other (provide details if material)	-	-
1.9	**Net cash from / (used in) operating activities**	**(795)**	**(415)**

2		**Cash flows from investing activities**		
2.1		Payments to acquire or for:		
	(a)	entities	-	-
	(b)	businesses	-	-
	(c)	property, plant and equipment	-	(13)
	(d)	investments	-	-
	(e)	intellectual property	-	-
	(f)	other non-current assets	-	-
2.2		Proceeds from disposal of:		
	(a)	entities	-	-
	(b)	businesses	-	-
	(c)	property, plant and equipment	-	-

Consolidated statement of cash flows			Current quarter $A'000	Year to date (12 months) $A'000
	(d)	investments	-	-
	(e)	intellectual property	-	-
	(f)	other non-current assets	-	-
2.3		Cash flows from loans to other entities	-	-
2.4		Dividends received (see note 3)	-	-
2.5		Other (provide details if material)	-	-
2.6		**Net cash from / (used in) investing activities**	**-**	**(13)**

3	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	552	970
3.6	Repayment of borrowings	(54)	(1,103)
3.7	Transaction costs related to loans and borrowings	(12)	(122)
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	**Net cash from / (used in) financing activities**	**486**	**(255)**

4	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	1,050	1,422
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(795)	(415)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	(13)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	486	(255)
4.5	Effect of movement in exchange rates on cash held	(1)	1
4.6	**Cash and cash equivalents at end of period**	**740**	**740**

5	**Reconciliation of cash and cash equivalents** at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	**Current quarter $A'000**	**Previous quarter $A'000**
5.1	Bank balances	740	1,050
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**740**	**1,050**

6	**Payments to related parties of the entity and their associates**	**Current quarter $A'000**
6.1	Aggregate amount of payments to related parties and their associates included in item 1	114
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

7	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	970	970
7.2	Credit standby arrangements	-	-
7.3	Other (insurance premium funding)	77	77
7.4	**Total financing facilities**	1,047	1047
7.5	**Unused financing facilities available at quarter end**		-

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

7.1: Short term loan facility with Sturt Capital Pty Ltd against the anticipated R&D Tax Incentive rebate for FY2026. The loan facility has an establishment fee of 1.5%, bears interest of 1.33% per month with a repayment date which is earlier of the date of receipt of the 2026 R&D Tax Incentive from the Australian Taxation Office and 31 December 2026. Principal outstanding at 30 June 2026 was $970,000.
7.3: Hunter Premium Funding, unsecured 10-month loan fully drawn in April 2027 for $113,668.70 to fund insurance premiums. Principal outstanding at 30 June 2026 was $76,683.98. The loan is repayable in monthly instalments at a flat annualised interest rate of approximately 6.1%.

8	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	(795)
8.2	Cash and cash equivalents at quarter end (item 4.6)	740
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	740
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	0.93
	Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.	

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

No. The Company does not expect to maintain the current level of net operating cash outflows. The Company is actively progressing revenue-generating initiatives and implementing cost management strategies aimed at improving operating cash flows in future periods

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Whilst the Company expects revenue to grow through the revenue-generating initiatives, the entity maintains flexibility to access additional funding if required (either debt or equity) and remains confident in its ability to do so, based on past success and market support.

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Yes. The entity expects to continue its operations and meet its business objectives based on current cash reserves, anticipated improvement in operating cash flows, and its demonstrated ability to raise capital when required.

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 30 July 2026

Authorised by: By the Board
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.